New Blood Pressure Shot Raises Eyebrows—and Questions

A six-month shot for blood pressure? Many of us rolled our eyes when saw those headlines.

Articles everywhere started blaring about a so-called game-changer for hypertension: a twice-yearly injection that could lower your blood pressure without the daily pill routine.

Does it sound convenient? Sure.Does it sound like another Big Pharma shortcut with major profit potential and unknown long-term risks? You bet.

Here’s what we know so far about this shiny new treatment—and why you might want to take a deep breath before jumping in line.

The drug is called zilebesiran, and it’s still in the testing phase. According to early study results from a Phase 2 clinical trial, a single injection can reduce blood pressure by 4 to 12 points—when added to daily medication.

Yes, you read that right. This isn’t a one-and-done cure. It’s an add-on to standard pills. And it’s only been tested for six months.

So, while some are already tossing around the word “breakthrough,” that’s a big leap for a very short-term study.

Zilebesiran works by targeting the liver, blocking a protein that kicks off your body’s blood pressure regulation system (called the RAAS system). It uses RNA interference to shut down a molecule called angiotensinogen at the source.

On paper, that sounds impressive. One shot, and blood pressure stays down for months? The pharmaceutical reps must be drooling.

But the RAAS system plays a role in far more than blood pressure. It’s involved in kidney function, fluid balance, and even your body’s response to stress. What happens when we meddle with that system long-term?

Right now, no one knows.

The short-term side effects reported so far include injection site reactions, low blood pressure, elevated potassium, and temporary kidney changes. Researchers say most of these were “mild” and “resolved on their own.”

We’ve heard that before.

The study excluded people with serious heart problems, kidney disease, or diabetes complications—the very folks most at risk from blood pressure issues.

So we have no idea how zilebesiran will behave in the real world, with real patients.

And let’s not forget who funded the trial: Alnylam Pharmaceuticals, the company developing the drug. Several researchers hold stock or received consulting fees. Draw your own conclusions.

Let’s zoom out. Nearly half of Americans have high blood pressure. But only 1 in 4 have it under control.

Why? Is it because we don’t have enough drugs?

No. It’s because the root causes of high blood pressure—like poor diet, lack of exercise, stress, and sleep issues—aren’t being addressed.

Natural strategies can work wonders:

• Daily walks can lower systolic BP by up to 10 points.
• Magnesium and potassium-rich foods support healthy arteries.
• Weight loss, better sleep, and stress reduction go a long way without a needle in sight.

But those don’t line Big Pharma’s pockets, do they?

If this shot helps someone who truly can’t manage their medication schedule, that’s great. But the long-term risks are still a mystery. And once again, we’re watching Big Pharma rush to market with a shiny new solution that skirts lifestyle change entirely.

So here’s our take: Don’t be pressured by the hype. If you and your doctor think the benefits outweigh the risks, that’s your call. Just make sure you have all the facts before you roll up your sleeve.

Because sometimes, the real solution doesn’t come in a syringe—it starts with what’s on your plate, how you move your body, and how well you sleep at night.

To making informed choices.

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Are sleep and blood pressure aging your brain faster?

Sources:

Staff, S. (2025, May 28). Game-Changer For High Blood Pressure? This New Shot Could Be It. Study Finds. https://studyfinds.org/zilebesiran-game-changer-for-high-blood-pressure-this-shot-could-be-it/